surmount-1 trial tirzepatide non-diabetic weight loss for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled Weight regain after the withdrawal

The drug primarily increases insulin secretion and decreases glucagon secretion in a glucose-dependent manner

17: Ard J, Lee CJ, Gudzune K, Addison B, Lingvay I, Cao D, Mast CJ, Stefanski A, Falcon B, Mojdami D

it takes under 30 seconds in the patient portal

doi: 10.1002/ejhf.2738 [DOI] [PubMed] [Google Scholar] 10.Kosiborod MN, Bhatt AS, Claggett BL, Vaduganathan M, Kulac IJ, Lam CSP, Hernandez AF, Martinez FA, Inzucchi SE, Shah SJ, et al

This ensures that patients who truly benefit receive safe support

Brand-name tirzepatide versus compounded: the real cost difference Brand-name tirzepatide comes in two FDA-approved forms